Metabolic Dysfunction in Hutchinson-Gilford Progeria Syndrome

Ray Kreienkamp1,2, Susana Gonzalo1

  • 1Edward A. Doisy Department of Biochemistry and Molecular Biology, Saint Louis University School of Medicine, St Louis, MO 63104, USA.

Cells
|February 13, 2020
PubMed

Insights

Hutchinson-Gilford Progeria Syndrome (HGPS) involves premature aging and cardiovascular issues. Metabolic interventions show promise for extending lifespan in HGPS animal models, offering new therapeutic avenues.

Area of Science:

  • Gerontology
  • Molecular Biology
  • Genetics

Background:

  • Hutchinson-Gilford Progeria Syndrome (HGPS) is a rare genetic disorder characterized by rapid, premature aging.
  • Patients with HGPS exhibit cardiovascular dysfunction, bone abnormalities, and adipose changes, mirroring aspects of normal aging.
  • Current HGPS research targets aging pathways like inflammation and DNA damage, but metabolic dysfunction is also a significant, less-understood factor.

Purpose of the Study:

  • To investigate the role of metabolism in Hutchinson-Gilford Progeria Syndrome.
  • To explore the therapeutic potential of metabolic interventions for HGPS.
  • To enhance understanding of HGPS pathophysiology and identify novel treatment strategies.

Main Methods:

  • Review of existing literature on HGPS and aging.
  • Analysis of metabolic pathways implicated in HGPS.
  • Examination of recent findings from HGPS animal models regarding metabolic interventions.

Main Results:

  • HGPS patients display severe metabolic problems.
  • Metabolic interventions in HGPS animal models have led to significant lifespan improvements.
  • These findings highlight the critical role of metabolism in HGPS progression.

Conclusions:

  • Metabolism is a key contributor to the pathophysiology of Hutchinson-Gilford Progeria Syndrome.
  • Targeting metabolic pathways represents a promising therapeutic strategy for HGPS.
  • Further research into HGPS metabolism could yield crucial advancements for treating this disease.

Related Concept Videos

Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
643
Overview of Protein Metabolism01:21

Overview of Protein Metabolism

Proteins are broken down into amino acids during digestion. Unlike fats and carbohydrates, which are stored for later use, proteins are not. Instead, amino acids are either used to produce ATP through oxidation or contribute to the creation of new proteins for the growth and repair of the body. Any surplus amino acids from the diet are converted into glucose or triglycerides rather than excreted.
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...
3.4K
Smooth Endoplasmic Reticulum01:21

Smooth Endoplasmic Reticulum

Smooth endoplasmic reticulum or smooth ER is a sub-organelle with specialized functions in animal cells and plant cells. It is often associated with the tubule morphology of the endoplasmic reticulum.
The ER provides optimal conditions for synthesizing steroid hormones and lipids, such as phospholipids and triglycerides. Traditionally, lipid metabolism was considered to be a smooth ER function. However, there is no direct evidence to prove that rough ER is completely excluded from lipid...
7.6K
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
146
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
304
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
4.4K